Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding by Glymour, M. Maria et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Initiation of antidepressant medication and risk of incident stroke: using the Adult 
Changes in Thought cohort to address time-varying confounding 
M. Maria Glymour SD1, Laura E. Gibbons PhD2, Paola Gilsanz SD3, Alden L. Gross PhD MHS
4
, Jesse Mez MD MS5, Paul W. Brewster PhD6, Jessica Marden SD7, Laura B. Zahodne PhD8,
Kwangsik Nho PhD9, Jamie Hamilton PhD10, Gail Li MD,PhD11, 12,  Eric B. Larson MD MPH2, 
13
, Paul K. Crane MD MPH2
1 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 
2
 Department of Medicine, University of Washington, Seattle, WA 
3
 Kaiser Permanente Division of Research, Oakland, CA 
4
 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and Johns 
Hopkins University Center on Aging and Health, Baltimore, MD
5 Alzheimer’s Disease and Chronic Traumatic Encephalopathy Center, Boston University School 
of Medicine, Boston, MA  
6
 Institute on Aging & Lifelong Health, University of Victoria, Victoria BC 
7
 Analysis Group, Boston, MA 
8 Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, 
Columbia University Medical Center, New York, NY 
9Center for Neuroimaging, Center for Computational Biology and Bioinformatics, Department of 
Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 
10
 Michael J. Fox Foundation for Parkinson's Research, New York, New York 
11
 Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care 
System, Seattle, WA 
12
 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 
13
 Kaiser Permanente Washington Health Research Institute, Seattle, WA 
Corresponding author: 
M. Maria Glymour
550 16th Street
San Francisco, CA 94158
Phone: 415 514 8140
mglymour@epi.ucsf.edu
Body word count: 3106 
Abstract word count: 196 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Glymour, M. M., Gibbons, L. E., Gilsanz, P., Gross, A. L., Mez, J., Brewster, P. W., … Crane, P. K. (2019). Initiation of 
antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying 
confounding. Annals of Epidemiology. https://doi.org/10.1016/j.annepidem.2019.04.010
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 - 2 -  
Abstract 
Purpose: Depression strongly predicts stroke incidence, suggesting that treating depression may 
reduce stroke risk. Antidepressant medications, however, may increase stroke risk via direct 
pathways. Prior evidence on antidepressant medication and stroke incidence is mixed. We 
evaluated associations between antidepressant use and incident stroke. 
Methods: For 2,302 Adult Changes in Thought cohort participants with no stroke at study entry, 
we characterized antidepressant use from pharmacy records, biennial depressive symptoms with 
a 10-item Centers for Epidemiologic Study- Depression (CES-D) scale, and incident strokes 
from ICD codes. We used discrete-time survival models with inverse probability weighting to 
compare stroke risk associated with filling antidepressant prescriptions; and by medication 
category: tricyclics (TCAs), selective serotonin reuptake inhibitors (SSRIs), or other.  
Results: Over an average 8.4-year follow-up, 441 incident strokes occurred. Filling 
antidepressant medications 3+ times versus 0-2 times predicted 35% increased odds of stroke 
(OR=1.35; 95% CI: 0.98, 1.66). Use of TCAs was associated with stroke onset (OR per 10 
fills=1.28; CI: 1.04, 1.57), but use of SSRIs (OR=0.98; CI: 0.80, 1.20) or other antidepressants 
(OR=0.99; CI: 0.67, 1.45) was not.  
Conclusions: Although patients who received antidepressant medication were at higher risk of 
stroke, this association appeared specific to TCA prescriptions.  
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Abbreviations: 
ACT Adult Changes in Thought  
CI Confidence Interval 
CES-D Centers for Epidemiologic Study- Depression 
ICD International Classification of Diseases 
MSM Marginal Structural Model 
OR Odds Ratio 
TCA Tricyclic Antidepressant 
SSRI Selective Serotonin Reuptake Inhibitor 
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Introduction:  
Depression in older adults is common and often undertreated (1). Clinical depression and 
depressive symptoms strongly predict incidence of stroke (2, 3), but it is not clear whether 
treating depressive symptoms would reduce stroke risk. Depression may influence stroke 
incidence via deleterious health behaviors or stress-related mechanisms (4, 5), but several prior 
studies reported that antidepressant medication use is associated with higher stroke incidence (2, 
6-9). The association between antidepressant use and stroke has been observed for several 
antidepressant classes, including SSRIs, TCAs, and other antidepressants, but evidence has been 
inconsistent (6, 10, 11). Elevated stroke risk among antidepressant users observed in prior studies 
may reflect the most severely depressed patients’ increased likelihood of receiving 
antidepressant medications, rather than a harmful effect of the antidepressants themselves, i.e., 
confounding by indication (12). Teasing apart relationships between depression severity, 
antidepressant medication use, and stroke risk is important for clinical decision making, 
especially in older adults who are at higher overall risk of stroke. 
Addressing this question is challenging because depression severity is potentially both a 
confounder and a mediator of the relationship between antidepressant use and depressive 
symptoms (figure 1). Few data sets include both detailed history of antidepressant use and 
continuous measures of symptom severity; even when data are available, analytic methods to 
handle time-varying confounding are necessary (13, 14). We used inverse probability weighting 
to estimate Marginal Structural Models assessing the impact of antidepressant medication use on 
stroke risk in a cohort of older adults with linked information from surveys and pharmacy 
records.  
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Methods: 
Sample 
The Adult Changes in Thought (ACT) cohort (15, 16) enrolled 3,392 cognitively intact, 
community dwelling adults 65 years or older in two enrollment phases (n=2,581 in 1994-1996, 
n=811 in 2000-2003), from a population-based integrated health care delivery system in King 
County, Washington (Group Health, now Kaiser Permanente Washington (KPW)). ACT initiated 
ongoing enrollments of 120-180 people per year in 2005. After obtaining informed consent, 
participants' demographic characteristics, medical history, and functional status were assessed 
using in-person biennial interviews. Each participant’s study information was linked to KPW 
medical records and pharmacy files. For the current analyses, among 4,131 consenting ACT 
participants with visits from inception (February 24, 1994) through data freeze (September 30, 
2012), we excluded anyone with a baseline stroke (diagnosis or self-report) or self-reported 
transient ischemic attack (n=426), and individuals who enrolled but had no follow-up (n= 40), 
leaving 3,665 eligible participants. We further excluded any participants with a history of 
antidepressant medication from 1977 (the inception of electronic pharmacy records in KPW) to 
enrollment (n=1,375). Our final analytic sample included 2,290 individuals followed until first 
stroke, death, or end of administrative follow-up. 
Measures 
Our outcome was first incident stroke, identified by ICD-9 codes included in the Center for 
Medicare and Medicaid Services’ Chronic Condition Data Warehouse algorithm (430, 431, 
433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.00, 434.01, 434.10, 434.11, 434.90, 434.91, 
435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02) extracted from inpatient and outpatient medical 
records. If the occasion with the putative stroke included any ICD codes associated with head 
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injury (800 to 804.9 inclusive or 850 to 854.1 inclusive), or if the principal diagnosis for the 
billing occasion was V57.xx (rehabilitation services), then the occasion was not considered a 
stroke, even if other ICD codes would have qualified as a stroke (these include events such as 
traumatic brain injury). If the diagnosis was based on outpatient services, we required two 
stroke-related records within 12 months of each other to qualify the event as a stroke (17-19).  
Our primary exposure, antidepressant medication use, including date of initiation and 
number of prescription fills, was extracted from KPW pharmacy records. Medications were 
categorized as any antidepressant, SSRI, TCA, or other antidepressant (see Appendix 1 for 
detailed medication listing). To avoid bias induced by individuals stopping antidepressants due 
to side effects or health concerns, our primary analyses focused on antidepressant initiation; this 
effectively categorized individuals as exposed to antidepressants for all time periods after their 
first prescription fill, even though many would have ceased using the medication.  
We considered several alternative approaches to coding antidepressant medications to 
confirm results were robust. We created an indicator for having filled 3 or more prescriptions for 
primary analyses. We conducted sensitivity analyses in which we enforced a 1-month lag 
between the antidepressant use and incident stroke, by excluding all strokes that occurred in the 
same month that antidepressant medication was initiated. Anticipating a potential dose-response 
association between duration of antidepressant medication use and stroke risk, we also 
considered a linear term for number of prescriptions filled (effects expressed in units of 10 
prescription fills). 
All models were adjusted for time-constant covariates: sex, years of education, non-white 
race/ethnicity, and age in years at baseline. We used inverse probability weighting (detailed 
below) to account for a set of covariates that were updated at each assessment wave. These 
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variables were selected because they were plausible predictors of both initiation of 
antidepressants and stroke risk. These variables were extracted from medical records or survey 
responses. Depressive symptom severity was assessed with the continuous score on a 10-item 
Centers for Epidemiologic Studies-Depression (CES-D) scale(20). Stroke risk was assessed with 
the components of the Framingham Stroke Risk Score, including: type II diabetes mellitus 
diagnosis, current smoking, systolic blood pressure, diagnoses of heart disease, atrial fibrillation, 
and left ventricular hypertrophy (21). Additional time-updated covariates included: marital status 
(married vs all other), self-rated health (5 point scale from excellent to poor), limitations in 
Activities of Daily Living (count of self-reported limitations in 6 activities), self-report of 
exercise 15+ minutes 3 times per week or more, cognitive function based on the Cognitive 
Abilities Screening Instrument (22), and body mass index (measured at clinic visits and self-
reported at intervening assessments). We have monthly data on exposures and outcome, but 
many covariates were assessed only at biennial assessment waves; we carried forward the most 
recent past covariate values.  
Statistical analysis:  
Marginal structural models are estimated by applying information from a model for the 
probability of treatment (antidepressant use) to an outcome model. We first evaluated the 
association of covariates, including depressive symptoms and other stroke risk factors, with the 
probability of initiating antidepressant medication use. These models were estimated defining 
each month of follow-up as a time interval and estimating odds of initiating antidepressants in 
that interval, censoring individuals after first antidepressant initiation (13). We focus on the 
exposure of ever having initiated antidepressant medication, so respondents were considered 
exposed in all months after their first prescription fill (and the corresponding probability of 
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subsequent exposures was 1 by definition, since nobody who once initiated can ever reverse that 
status). We adopted a similar approach to account for selective attrition from the sample 
(estimating the probability the respondent remained in the sample), and the final weights were 
the product of confounding weights and attrition weights. We used stabilized weights, with the 
numerator equal to the estimated probability of receiving the treatment s/he received given time-
constant covariates and the denominator estimated additionally including time-varying covariates 
(23).  
We then estimated the outcome model, which was a discrete-time survival model for 
incident stroke with each outcome interval (i.e., each month during which a stroke might occur) 
reweighted based on the inverse of the probability the individual received the treatment he or she 
actually received in the prior month. Outcome models were estimated using a logit link in a 
weighted generalized linear regression model with sandwich variance estimators, in each month 
of observation and censoring after first recorded stroke. This model included a cubic spline to 
account for time since enrollment. Because stroke is rare, the logit model approximates a hazard. 
All time-constant variables used to estimate the numerators of the stabilized weights were 
included in the regression models.  
For models of specific antidepressant class, the ideal model would reweight based on the 
probability of using the specific antidepressant, but these models did not converge, so we could 
only incorporate weights for use of any antidepressant.   
We conducted several secondary analyses to assess the robustness of our findings. We 
estimated models restricting to individuals who ever had a depression diagnosis. Another set of 
models specified exposure as a count of prescriptions filled (in units of 10) and used this count to 
predict stroke in the overall sample and in analyses restricted to only those individuals with at 
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least one antidepressant prescription fill. To rule out potential confounding due to individuals 
taking antidepressants for pain-related diagnoses, we repeated analyses excluding time at risk 
which accrued after any diagnosis related to pain (ICD codes: 307.81, 339.10-339.12, 339.42, 
339.44, 339.89, 346.0-346.99, 355.9, 356.9, 729.2, 784.0). To evaluate the potential for bias due 
to the secular trend in the popularity of SSRIs, we tested whether estimated effects of 
antidepressant use differed before and after the year 2000. 
To facilitate comparison with previous research (2, 6-9), we also estimated conventional 
models with or without adjustment for time-varying confounders, in which we did not apply 
weights. 
 
Results 
Over an average of 8.4 years of follow-up, 441 incident first strokes were recorded (stroke rate 
=2.2 per 100 person-years). At least one antidepressant prescription was filled during the follow-
up period by 30% of the sample (Table 1). Predictors of initiation of antidepressant use included 
depressive symptoms (OR per additional depressive symptom=1.07; 95% CI:1.05, 1.10), female 
sex, lower education, worse self-reported health, more ADL limitations, and worse cognitive 
function (Table 2).  
Stroke incidence was non-significantly elevated in participants who initiated any 
antidepressant medication (OR=1.23; 95% CI: 0.95, 1.62; Table 3), and those who filled 3 or 
more prescriptions (OR=1.35; 95% CI: 0.98, 1.86). The odds of stroke incidence were estimated 
to increase by 8% per ten prescription fills (OR=1.08; 95% CI: 0.93, 1.26), with CIs that 
included the null; results were identical in the full sample or when restricting to those with at 
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least one prescription fill. Risk was significantly elevated when restricting to individuals who 
had a diagnosis of depression at some point during follow-up (OR=1.84; 95% CI: 1.08, 3.14). 
Focusing on the class of antidepressant, TCA use was significantly associated with stroke 
(OR=1.28; 95% CI: 1.04, 1.57). Associations between stroke and SSRI use (OR=0.98; 95% CI: 
0.80, 1.20) or other antidepressants (HR=0.99; 95% CI: 0.67, 1.45) were null. 
We found little evidence that the associations differed in more recent periods of follow-
up, with non-significant albeit positive (larger associations in later years) interactions of an 
indicator of follow-up after January 1, 2000 with both SSRI use (interaction b=.35, p=0.56) and 
TCA use (interaction b=1.27, p=0.08). When excluding risk periods after pain-related diagnoses, 
results were similar (TCA HR per ten refills=1.36; 95% CI: 1.10, 1.70; SSRI HR per ten 
refills=1.01; 95% CI: 0.81, 1.25; other anti-depressant HR per ten refills=1.06; 95% CI: 0.67, 
1.69). 
 
Discussion 
In a large and well-characterized cohort of older adults, we confirmed the link between initiation 
of antidepressants and several risk factors previously documented to predict stroke. After 
accounting for these risk factors, including time-updated self-reported depressive symptoms, 
antidepressant use was associated with moderate increases in stroke risk, although the CIs were 
wide and included the null. When examining class of antidepressant medications, risk was 
significantly elevated only for TCAs, whereas risk associated with SSRIs was null. The absolute 
impact of the risk associated with TCA use would depend on the underlying incidence rate of 
stroke for each patient, but given an absolute stroke rate of 2.2 per 100 person years, an elevated 
risk of 28% would indicate 0.6 extra strokes per 100 person-years.  
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Our findings confirm the importance of accounting for depressive symptoms and other 
self-reported stroke risk factors when modeling associations of antidepressants with stroke risk. 
Depression and elevated depressive symptoms are robustly linked to stroke incidence, with meta-
analyses suggesting a 34-45% increase in stroke hazard (2, 3). Depressed individuals are more 
likely to use antidepressant medications, with a 60% elevation a plausible lower bound 
(approximately as predicted by our models of antidepressant use assuming depressed people 
have a 7 point higher CES-D score than non-depressed). If depressed individuals also have a 
40% elevation in stroke risk, this implies that simply due to confounding by indication, we 
would expect antidepressant users to have approximately a 24% higher risk of stroke than non-
users in analyses that did not account for symptoms. The actual bias is probably larger because 
factors such as cognitive functioning, which strongly predict stroke (24-26), were also associated 
with initiating antidepressants, independently of CES-D score. Self-reported risk factors, such as 
self-rated health and ADL limitations, rather than conditions associated with diagnosis codes, 
were the most salient predictors of antidepressant initiation. Such self-reported variables are 
rarely available in analyses based on administrative records.  
Much prior work restricts analyses to individuals with a diagnosis of depression in order 
to reduce confounding by indication, but even among individuals with depression, severity of 
depression predicts initiation of and type of antidepressants. In the ACT cohort, each one point 
higher CES-D score was associated with a 5% higher odds of initiating antidepressant 
medication among individuals who ever received a diagnosis of depression. Thus, even when 
restricting to people who received a depression diagnosis, symptom severity may have 
confounded the association between antidepressant medication use and stroke risk. In analyses 
restricted to study participants with a diagnosis of major depression, the estimated effect of 
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antidepressant use on stroke was more adverse than when estimated among the overall ACT 
sample. This suggests that, surprisingly, restricting to individuals with depression may 
exacerbate confounding of the association between antidepressant use and risk of stroke. 
Antidepressant use in the absence of diagnosed depression appears common (27). Patients who 
choose not to use antidepressant medication despite a diagnosis of major depression may be 
especially health-conscious or pursue other strategies to manage depression symptoms that have 
health benefits (e.g., increased physical activity). This may exacerbate the extent of confounding 
in analyses restricted to individuals with a diagnosis of depression. 
Prior findings on the associations between antidepressant use and stroke risk are 
inconsistent, with the bulk of the evidence suggesting elevated stroke risk is associated with 
antidepressant use. A 2014 meta-analysis of studies of SSRI use and incident stroke identified 
only four prior cohort studies, with a pooled adjusted odds ratio of 2.12 (95 % CI 1.25–3.61)(8). 
Few prior studies incorporate control for confounding by indication: among those four, only two 
included any control for depression severity (6, 7), and an additional more recent cohort study 
included control for a binary indicator of depressive symptoms(28). Combining our effect 
estimate of 0.98 with these three prior cohort studies gives an inverse-variance weighted effect 
estimate of 1.15 (95% CI: 1.02, 1.29) for the effect of SSRIs on risk for stroke. Thus, a best 
estimate incorporating both our findings and results from the handful of previous studies 
addressing confounding by indication is a small increase in stroke risk, although analyses that do 
not include control for a continuous symptom severity measure may have additional residual 
confounding. More evidence to provide greater precision and explain why effect estimates differ 
between cohorts would be valuable.   
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Prior evidence on TCAs and stroke is also inconsistent. Some studies suggest TCA users 
are at higher risk of stroke than either non-users or SSRI users (11), while others report TCA use 
has no association with stroke risk (7). Inconsistent findings may partially reflect differences in 
practice patterns such that TCAs or SSRIs are systematically prescribed to individuals with more 
severe depression. Our results suggest a modest elevation in risk associated with TCA use. 
The impact of antidepressants on stroke risk is of particular importance given recent 
interest in prescribing SSRIs to foster post-stroke neurologic reorganization even in non-
depressed stroke survivors(29-32). Although we focus on first strokes, the mechanism via which 
antidepressants influence first stroke risk is likely relevant to recurrent stroke. The potential 
impact on recurrent stroke risk is important to evaluate if we are moving towards universal 
antidepressant treatment for stroke survivors, but will require a much larger sample to evaluate 
appropriately.  
The ACT cohort is too small to support separate analyses of ischemic and hemorrhagic 
stroke. Prior work links SSRIs to hemorrhagic events, but effect sizes are so small they would 
likely be undetectable in ACT (33). There is also limited evidence on the potential for depressive 
symptoms to confound associations between SSRI and hemorrhagic stroke (2).  Our results are 
from a highly-educated and predominantly white sample. We know of no compelling evidence 
that biological effects of antidepressants on stroke risk differ by socioeconomic factors or race, 
but there is little research on effects of antidepressants in racial/ethnic minorities (34). Our 
interpretation relies on the assumption of no unmeasured confounding, as in any observational 
study. Our control variables represent an unusually comprehensive list compared to other studies, 
but this assumption is unverifiable. One possible explanation for the elevated stroke risk 
associated with TCA use is that the CES-D does not adequately capture the depression severity 
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that influences likelihood of TCA initiation. Because TCAs are often used as 2nd line therapy for 
resistant depression, suggesting symptoms may be especially severe or persistent in TCA users, 
the possibility that CES-D does not capture depression severity that influences TCA initiation is 
a particular concern for estimates of the effects of TCA use. Similarly, the most recent CES-D 
score available from ACT study visits may not adequately capture the features of depression that 
predict stroke (35). However, the association between the unobserved aspect of depression 
severity and likelihood of TCA use would have to be quite substantial to account for the 
observed association (36). Regardless, our findings would ideally be confirmed using evidence 
from randomized trials.  
Despite these limitations, our analyses make important advances in this important 
research area. To our knowledge, no prior study has implemented statistical analyses appropriate 
to control for confounding variables that may partially mediate the effects of antidepressants, as 
is the case with depressive symptoms (13, 14). The design of ACT, integrating cohort-based 
assessments with administrative information from a large health care provider, provides an 
unusually rich set of covariates to control for confounding by indication.  
The current findings from our study and others suggest little adverse effect of SSRIs on 
incident stroke risk. The evidence for TCAs is more worrisome, suggesting moderate excess 
stroke risk associated with using TCAs, although estimates for TCAs may also be more 
vulnerable to confounding, and TCAs, unlike SSRIs, are not currently recommended as post-
stroke prophylaxis. The results support the possibility of exploring non-pharmaceutical options 
to address depressive symptoms, although with persistent depression, the quality of life benefits 
of antidepressant pharmacotherapy may outweight any adverse impacts on stroke risk. The 
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specific findings that SSRIs had little associated stroke risk support the predominance of SSRIs 
as the preferred pharmaceutical therapy for depression (1, 37, 38).  
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Figure 1. Depressive symptom severity as a time-varying confounder that concurrently partially mediates the relationship 
between antidepressant use and stroke. Antidepressant use at time 2 (t2) is both influenced by previous depressive symptom 
severity (t1) and influences future depressive symptom severity (t3). Prior evidence indicates that depressive symptoms directly 
influence stroke risk, so depressive symptom severity both confounds and is a partial mediator for the effects of antidepressants. 
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Table 1. Description of Adult Changes in Thought Cohort 
Full cohort 
Ever used an 
anti-depressant 
Ever used a 
Tricyclica 
Ever used an 
SSRIa 
mean/N %/SD mean/N %/SD mean/N %/SD mean/N %/SD 
Total 2209 100% 690 100% 479 100% 378 100% 
Incident stroke cases 441 19% 128 19% 95 20% 80 21% 
Years of follow-up 8.4 5.5 10.9 5.1 10.8 5.2 11.0 4.9 
Baseline time-constant covariates     
Male 1105 48% 267 39% 190 40% 135 36% 
Years of education 14.8 3.2 14.2 3.1 14.1 3.2 14.0 3.0 
Race other than white 194 8% 54 8% 40 8% 26 7% 
Baseline values of time-varying covariates      
Age 74.3 6.3 74.9 6.2 74.6 6.2 75.2 5.9 
CES-D score (0-30) 2.9 3.3 3.7 3.5 3.7 3.6 3.8 3.7 
Framingham Stroke risk Score 8.6 7.4 8.4 7.1 8.2 6.7 8.4 7.0 
Diabetes 205 9% 63 9% 44 9% 32 7% 
Smoking (current vs all other) 97 4% 38 6% 25 5% 21 6% 
Hypertension 844 37% 256 37% 169 35% 157 42% 
Average systolic blood pressure 140 21 141 21 141 21 143 21 
Heart disease 374 16% 117 17% 80 17% 66 18% 
Atrial fibrillation 169 7% 37 5% 26 5% 19 5% 
Left ventricular hypertrophy 52 2% 7 1% 4 1% 4 1% 
Married or living as married 1368 60% 395 57% 278 58% 220 58% 
Self-rated health (1 excellent - 5 poor) 2.4 0.9 2.6 0.9 2.6 0.9 2.6 0.9 
Count of ADL limitations (0-6) 0.2 0.7 0.3 0.7 0.3 0.7 0.3 0.6 
Cerebrovascular composite score (ever stroke, ever 
TIA, ever CEA) 13 0% 3 0% 2 0% 3 1% 
Exercise regularly (15+ minutes at least 3x per 
week)) 1673 73% 495 72% 347 73% 266 71% 
IRT CASI score (-4 to 1.75) 0.35 0.7 0.28 0.71 0.29 0.73 0.26 0.69 
  Body Mass Index 27.2 4.8   27.2 4.8 27.3 4.9 27.3 4.6 
a
 Some participants used both tricyclics and SSRIs. 
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Table 2. Predictors of Antidepressant Use in the Adult Changes in Thought Cohort 
Baseline covariates 
Baseline and time-
dependent covariates 
OR 95% CI OR 95% CI 
Female 1.38 1.18 1.61 1.51 1.26 1.81 
Education (years) 0.96 0.94 0.99 0.99 0.97 1.02 
White 1.15 0.87 1.52 1.32 0.96 1.80 
Age 1.03 1.02 1.05 1.01 0.99 1.02 
Cubic spline for time 
(months) 
  Intercept 1.00 0.99 1.02 1.01 0.99 1.02 
  Linear term 0.92 0.76 1.13 0.89 0.73 1.09 
  Quadratic term 1.23 0.79 1.94 1.34 0.83 2.14 
  Cubic term 0.80 0.56 1.16 0.77 0.52 1.12 
Framingham Stroke Risk 
score 1.00 0.99 1.01 
CES-D score 1.07 1.05 1.10 
Married or live with partner 1.05 0.88 1.25 
Self-rated health 1.23 1.12 1.36 
ADL limitations 1.11 1.02 1.22 
Cerebrovascular composite  1.54 1.08 2.19 
Exercise regularly  0.97 0.82 1.15 
IRT CASI score 0.75 0.67 0.84 
Body Mass Index         0.99 0.98 1.01 
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Table 3. Antidepressant Use and Incident Stroke in the Adult Changes in Thought Cohort 
    
Conventional Models, 
adjusted for baseline 
covariates 
  
Conventional Models, 
adjusted for baseline 
and time-dependent 
variables 
 
Marginal 
Structural Models 
HR 95% CI HR 95% CI HR 95% CI 
Any use among full sample 
Never received antidepressant 1.00 
   
1.00 
 
1.00 
At least one prescription 1.14 0.92 1.41 
 
0.97 0.76 1.23 1.23 0.95 1.62 
Filling 3+ prescriptions among full sample 
   
<=2 prescriptions 1.00 
   
1.00 
 
1.00 
3+ prescriptions 1.36 1.05 1.76 
 
1.21 0.90 1.61 1.35 0.98 1.86 
Any use among ever-diagnosed depressed 
    
Never received antidepressant 1.00 
   
1.00 
 
1.00 
At least one prescription 1.70 1.07 2.71 
 
1.26 0.76 2.09 1.84 1.08 3.14 
Number of prescriptions filled among full sample 
    
Per ten refills 1.06 0.99 1.15 
 
1.03 0.93 1.14 1.08 0.93 1.26 
Number of prescriptions filled among people with at least one prescription 
 
Per ten refills 1.11 1.02 1.20 
 
1.03 1.01 1.26 1.08 0.93 1.26 
Type of medication among full sample 
     
No antidepressants 1.00 
   
1.00 
 
1.00 
TCA 1.16 1.03 1.31 
 
1.18 1.02 1.38 1.28 1.04 1.57 
SSRI 1.01 0.90 1.14 
 
0.93 0.78 1.10 0.98 0.80 1.20 
  
Other medication 0.98 0.68 1.43   1.08 0.74 1.56 
  0.99 0.67 1.45 
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Appendix 1. Medication categories 
  
Tricyclics 
 
Serotonin-2 antagonist/reuptake inhibitors (SARIS) 
Nefazodone       
Trazodone 
 
Tricyclic antidepressants & rel. Non-sel. Ru-inhib 
Amitriptyline 
Amoxapine 
Clomipramine 
Desipramine 
Doxepin 
Imipramine 
Maprotiline 
Nefazodone 
Nortriptyline 
Protriptyline 
Trazodone 
 
SSRIs 
Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine maleate 
Paroxetine  
Sertraline 
 
Other antidepressants 
 
Alpha-2 receptor antagonist antidepressants      
Mirtazapine           
 
Norepinephrine and dopamine reuptake inhib (NDRIS)    
Bupropion 
 
Serotonin-norepinephrine reuptake-inhib (SNRIS)     
Duloxetine       
Venlafaxine       
 
Maois - non-selective & irreversible        
Isocarboxazid  
Marplan 
Tranylcypromine             
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